Targeted Genetics (TGEN) said today that it has cut about 10 percent of its workforce and shifted its research efforts in a bid to survive a cash crunch.
Targeted Genetics said today that it has cut about 10 percent of its workforce and shifted its research efforts in a bid to survive a cash crunch.
The Seattle biotechnology company said it will focus on a promising experimental therapy to treat a genetic eye disease, and on two other early-stage products that haven’t been tested in humans yet. The company is shifting resources away from its current lead product, a gene therapy to treat inflammatory arthritis, and is considering seeking a partner to take on the expensive clinical trials required to get the drug to market.
Targeted Genetics has laid off seven employees, and its seven most senior executives are taking salary deferrals or have been reduced to half-time status. Those changes will result in a 25 percent cut in payroll expenses. The company now employs 56 full-time-equivalent employees, it said in a statement.
Targeted Genetics, whose founding chief executive H. Stewart Parker departed last month, has cash to last it through the first quarter of 2009.
Most Read Business Stories
- FAA safety engineer goes public to slam the agency's oversight of Boeing's 737 MAX
- MacKenzie Scott marries Seattle teacher after Bezos divorce
- 55,000 in Washington state may have to pay back thousands in jobless benefits
- Microsoft’s $10 billion Pentagon deal at risk amid Amazon fight
- 1 house, 45 offers: Homebuyers in Western Washington hard-pressed as supply remains scarce
The company has struggled since a patient died during a clinical trial for its inflammatory arthritis therapy in July 2007. Its stock price plummeted, and never recovered, even after federal researchers determined that the product was not directly responsible for the patient’s death. Now the company faces an uphill battle to survive in an environment where investors are leery of investing in small biotechs.
“We believe this prioritization of our product pipeline and the resulting changes to our cost structure positions us to advance our promising candidates while we explore ways to monetize other valuable assets that the company has built over the years,” said B.G. Susan Robinson, president and chief executive officer, in a statement.
Targeted Genetics’ stock closed up 6 cents, or 27.3 percent, at 28 cents today.
Ángel González: 206-515-5644 or firstname.lastname@example.org